HET(病史、心电图和肌钙蛋白)评分在美国多中心队列中效能低且阴性预测值不足
本研究为STOP-CP多中心队列的二次分析,纳入1460例急诊胸痛患者,由接诊医生前瞻性判定HEART与HET评分成分,比较两者对30天心脏死亡或心肌梗死的阴性预测值(NPV)及低危分层效能。结果显示,HET评分低危组30天事件率1.4%(4/286),NPV 98.6%(95%CI 96.5-99.6%);HEART评分低危组事件率2.2%(12/534),NPV 97.8%(95%CI 96.1-98.8%),两者NPV差异无统计学意义(p=0.29)。HET评分效能(低危比例)为19.6%(286/1460,95%CI 17.6-21.6%),显著低于HEART评分的36.6%(534/1460,95%CI 34.1-39.1%)(p<0.001)。结论认为,两种评分均未达到安全NPV阈值,HET评分效能显著更低。
要点
- 在1460例急诊胸痛患者中,HET评分低危组30天心脏死亡或心肌梗死发生率为1.4%(4/286),NPV为98.6%(95%CI 96.5-99.6%),未达到预设的NPV≥99%安全阈值。
- HEART评分低危组30天事件率为2.2%(12/534),NPV为97.8%(95%CI 96.1-98.8%),同样未达到NPV≥99%安全阈值。
- HET评分与HEART评分的NPV差异无统计学意义(p=0.29)。
- HET评分低危分层效能为19.6%(286/1460,95%CI 17.6-21.6%),显著低于HEART评分的36.6%(534/1460,95%CI 34.1-39.1%)(p<0.001)。
- 作者结论认为,在美国多中心队列中,HET评分和HEART评分均未实现安全的NPV,HET评分效能显著低于HEART评分。
适用人群与场景
- 急诊科胸痛患者,来源于STOP-CP多中心队列研究,共1460例,其中女性46.3%(676/1460),平均年龄57.6±12.8岁。
诊断标准与关键阈值
- 采用HEART评分和HET评分将患者分为低危、中危和高危三层,风险评分成分由接诊医生前瞻性判定。
- 安全性定义为30天心脏死亡或心肌梗死的阴性预测值(NPV)≥99%,沿用既往研究普遍接受的阈值。
研究设计与关键结果
- 研究类型为STOP-CP多中心队列研究的二次分析,纳入1460例急诊胸痛患者,由接诊医生前瞻性判定HEART和HET评分成分,主要安全终点为30天心脏死亡或心肌梗死。
- 30天心脏死亡或心肌梗死总发生率为12.7%(186/1460)。
- HET评分低危组30天心脏死亡或心肌梗死发生率为1.4%(4/286),NPV为98.6%(95%CI 96.5-99.6%);HEART评分低危组发生率为2.2%(12/534),NPV为97.8%(95%CI 96.1-98.8%);两者NPV比较p=0.29。
- HET评分低危分层效能为19.6%(286/1460,95%CI 17.6-21.6%),HEART评分为36.6%(534/1460,95%CI 34.1-39.1%),HET显著低于HEART(p<0.001)。
证据类型、等级与局限
- 证据类型:多中心队列研究的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,在美国多中心队列中,HET评分与HEART评分均未达到安全的NPV(NPV≥99%),HET评分效能显著低于HEART评分。
指南或共识出处
- STOP-CP研究(High-Sensitivity Cardiac Troponin T to Optimize Chest Pain Risk Stratification;ClinicalTrials.gov: NCT02984436)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: The History, Electrocardiogram, and Troponin (HET) score is a simplified alternative to the HEART score for risk stratifying emergency department (ED) patients with chest pain. This study evaluates the safety and efficacy of the HET score for 30-day cardiac death or myocardial infarction (MI).
METHODS: We conducted a secondary analysis of the STOP-CP multisite cohort study. Risk score components were determined prospectively by the treating provider. Patients were classified into low-, intermediate-, and high-risk strata based on HEART and HET scores. Negative predictive value (NPV) was calculated for the primary safety outcome of cardiac death or MI at 30 days. Consistent with prior studies, the commonly accepted threshold of NPV ≥ 99 % was used to define safety. Efficacy was the proportion of patients classified as low risk. NPV and efficacy were compared between HET and HEART scores using generalized score statistic and McNemar's test, respectively.
RESULTS: Among 1460 patients, 46.3 % (676/1460) were women and the mean age was 57.6 ± 12.8 years. Cardiac death or MI at 30 days occurred in 12.7 % (186/1460). Among patients with a low-risk HET score, 1.4 % (4/286) experienced 30-day cardiac death or MI, while 2.2 % (12/534) of patients with a low-risk HEART score had 30-day cardiac death or MI. This yielded a NPV for 30-day of 98.6 % (95 % CI 96.5-99.6 %) for the HET score vs 97.8 % (95 % CI 96.1-98.8 %) for the HEART score (p = 0.29).Efficacy of the HET score was 19.6 % (286/1460, 95 % CI 17.6-21.6 %) vs 36.6 % (534/1460, 95 % CI 34.1-39.1 %) for the HEART score (p < 0.001).
CONCLUSION: In a multisite US cohort study, neither the HET score nor the HEART score achieved a safe NPV. The HET score had significantly lower efficacy than the HEART score.
TRIAL REGISTRATION: High-Sensitivity Cardiac Troponin T to Optimize Chest Pain Risk Stratification (STOP-CP; ClinicalTrials.gov: NCT02984436; https://clinicaltrials.gov/ct2/show/NCT02984436).
参考来源
- Supples MW, Dameron AG, Powell S, et al. The HET (history, electrocardiogram, and troponin) score has low efficacy and negative predictive value in a multisite U.S. cohort study. Am J Emerg Med. 2024. PMID: 39729682. doi:10.1016/j.ajem.2024.12.012
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。